Company Profile

Biodesy LLC (AKA: Biodesy Inc)
Profile last edited on: 8/30/2019      CAGE: 46M73      UEI: X5NEJGZBNAT5

Business Identifier: Protein function analysis systems for drug discovery and development
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

384 Oyster Point Boulevard Unit 8
South San Francisco, CA 94080
   (650) 871-8716
Location: Single
Congr. District: 15
County: San Mateo

Public Profile

Biodesy is a life science instrumentation company developing a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein. The technology can be used to measure functional activation in a protein upon binding drugs or ligands, in real time and without the need for a crystal structure. Previously located in New York City, Biodesy has developed a unique and entirely new means of detecting structural change in proteins and other biological molecules. The activity of a protein is determined by the specific structure it adopts out of the multiple ones available to it, and so a drug that favors a particular conformation will be more precise and selective in its action. The technology is also the first to enable the direct discovery of allosteric modulators. Allosteric modulators hold great promise as therapeutics. They change a protein's conformation, or stabilize an inactive one, by mimicking the natural way in which protein activity is regulated rather than competing with endogenous ligand, which can disrupt healthy processes. The firm has developed general assays of conformational change for beta-amyloid peptide monomers, integrins, and kinases. These assays can be used to discover new drugs for Alzheimer’s disease and a number of cancers, including breast cancer. Additional applications include, but are not limited to, GPCRs, phosphatases, proteases and ion channels.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Joshua S Salafsky -- Founder

  Greg Yap -- CEO and Co-Founder

  Neil Kennedy -- Vice President, Head Of Product Development

  Ben Moree

  Ariel Notcovich -- Vice President, Head of Product Development